Raf Inhibitors

BRaf

c-Raf

Raf

Raf Degraders & Inhibitors

Product Name	BRaf	c-Raf	Raf	Purity
Sorafenib	Braf, IC₅₀: 22 nM Braf^V599E, IC₅₀: 38 nM	Raf-1, IC₅₀: 6 nM		99.92%
Dabrafenib	BRaf^V600E, IC₅₀: 0.6 nM	CRAF, IC₅₀: 5 nM		99.94%
Vemurafenib	B-Raf^V600E, IC₅₀: 31 nM	c-Raf-1, IC₅₀: 48 nM		99.85%
Regorafenib	BRaf^V600E, IC₅₀: 19 nM Braf, IC₅₀: 28 nM	Raf-1, IC₅₀: 2.5 nM		99.93%
Doramapimod	B-Raf, IC₅₀: 83.4 nM			99.98%
RMC-7977		c-Raf		99.48%
SB-590885	B-Raf, Ki: 0.16 nM	c-Raf, Ki: 1.72 nM		99.77%
Sorafenib Tosylate	Braf, IC₅₀: 22 nM Braf^V599E, IC₅₀: 38 nM	Raf-1, IC₅₀: 6 nM		99.91%
Avutometinib	BRaf^V600E, IC₅₀: 8.2 nM Braf, IC₅₀: 190 nM	CRAF, IC₅₀: 56 nM		99.02%
PLX-4720	B-Raf^V600E, IC₅₀: 13 nM B-Raf, IC₅₀: 160 nM			99.91%
Tovorafenib			RAF	99.89%
Belvarafenib	BRaf^V600E, IC₅₀: 7 nM B-Raf, IC₅₀: 56 nM	CRAF, IC₅₀: 5 nM		99.71%
Naporafenib	Braf, IC₅₀: 0.21 nM	CRAF, IC₅₀: 0.072 nM		99.86%
LY3009120	BRaf^V600E, IC₅₀: 5.8 nM Braf, IC₅₀: 9.1 nM	CRAF, IC₅₀: 15 nM		98.97%
GW 5074		c-Raf, IC₅₀: 9 nM		99.49%
Dabrafenib Mesylate	BRaf^V600E, IC₅₀: 0.6 nM	CRAF, IC₅₀: 5 nM		99.95%
GDC-0879	B-Raf, IC₅₀: 0.13 nM			99.69%
Exarafenib			RAF	99.68%
AZ 628	B-Raf, IC₅₀: 105 nM B-Raf^V600E, IC₅₀: 34 nM	c-Raf-1, IC₅₀: 29 nM		99.85%
Lifirafenib	BRaf^V600E, IC₅₀: 23 nM			98.73%
Agerafenib	Braf, Kd: 36 nM BRaf^V600E, Kd: 14 nM	CRAF, Kd: 39 nM		99.63%
Regorafenib monohydrate	BRaf^V600E, IC₅₀: 19 nM Braf, IC₅₀: 28 nM	Raf-1, IC₅₀: 2.5 nM		99.96%
Regorafenib Hydrochloride	BRaf^V600E, IC₅₀: 19 nM Braf, IC₅₀: 28 nM	Raf-1, IC₅₀: 2.5 nM		99.58%
TAK-632	Braf, IC₅₀: 8.3 nM	c-Raf, IC₅₀: 1.4 nM		98.84%
RAF265			RAF	99.80%
Plixorafenib	BRaf^V600E, IC₅₀: 5 nM			99.94%
PLX7904	BRaf^V600E, IC₅₀: 5 nM (in mutant RAS expressing cells)			98.94%
Rineterkib			RAF	99.83%
CFT1946	BRaf^V600E			99.84%
CCT196969	BRaf^V600E, IC₅₀: 0.04 μM Braf, IC₅₀: 0.1 μM	CRAF, IC₅₀: 0.01 μM		99.36%
Raf inhibitor 1	B-Raf, Ki: 1 nM B-Raf^V600E, Ki: 1 nM	c-Raf, Ki: 0.3 nM		98.11%
BI-882370	Braf, IC₅₀: 0.6 nM BRaf^V600E, IC₅₀: 0.4 nM	c-Raf, IC₅₀: 0.8 nM		99.16%
AD80			RAF	99.88%
RAF709	Braf, IC₅₀: 0.4 nM	CRAF, IC₅₀: 0.5 nM		99.45%
L-779450	B-Raf, Kd: 2.4 nM			98.75%
ZM 336372		c-Raf, IC₅₀: 0.07 μM (0.1 mM ATP)		98.42%
B-Raf IN 11	B-Raf^V600E, IC₅₀: 76 nM BRAF^WT, IC₅₀: 238 nM			99.55%
PROTAC BRAF-V600E degrader-1	BRAF-V600E, Kd: 2 nM Braf, Kd: 2.4 nM			98.02%
BRAF inhibitor	B-Raf			98.97%
MCP110			RAF	99.82%
HG6-64-1	B-Raf^V600E, IC₅₀: 0.09 μM (in Ba/F3 cells)			99.69%
PROTAC B-Raf degrader 1	B-Raf			99.78%
Tinlorafenib	BRaf^V600E, IC₅₀: 4.25 nM			98.20%
GNE-9815	Braf, Ki: 0.19 nM	CRAF, Ki: 0.062 nM		98.28%
B-Raf IN 2	BRaf^V600E			98.29%
AZ304	BRaf^V600E, IC₅₀: 38 nM BRAF^WT, IC₅₀: 79 nM	CRAF, IC₅₀: 68 nM		99.96%
Uplarafenib	Braf, IC₅₀: 50-100 nM BRAF-V600E, IC₅₀: < 50 nM			99.15%
RAS/RAS-RAF-IN-1			RAF	99.81%
LUT014	B-Raf, IC₅₀: 11.7 nM
B-Raf IN 1	B-Raf, IC₅₀: 24 nM			99.94%
KG5	B-Raf	c-Raf		99.79%
AD57	Braf			98.08%
Regorafenib mesylate	B-Raf, IC₅₀: 28 ± 10 nM BRaf^V600E, IC₅₀: 19 ± 6 nM	Raf-1, IC₅₀: 2.5 ± 0.6 nM
(Z)-GW 5074		c-Raf
RAF mutant-IN-1	B-Raf^V600E, IC₅₀: 30 nM BRAF^WT, IC₅₀: 392 nM	C-RAF^340D/Y341D, IC₅₀: 21 nM
Takeda-6D	Braf, IC₅₀: 7.0 nM
B-Raf IN 13	BRaf^V600E, IC₅₀: 3.55 nM
ML786 dihydrochloride			RAF, IC₅₀: 2.1 nM
ARQ-736	B-Raf
CCT241161	Braf, IC₅₀: 30 nM BRaf^V600E, IC₅₀: 15 nM	CRAF, IC₅₀: 6 nM
B-Raf IN 8	B-Raf, IC₅₀: 70.65 ± 0. nM
RAF-IN-1	BRaf^V600E, IC₅₀: 29.4 nM BRAF^WT, IC₅₀: 36 nM	c-Raf, IC₅₀: 3.8 nM
VEGFR-2/BRAF-IN-1	BRaf^V600E, IC₅₀: 0.063 μM BRAF^WT, IC₅₀: 0.005 μM
MEK/RAF-IN-1	Braf, IC₅₀: 3 nM BRaf^V600E, IC₅₀: 3 nM
PROTAC BRAF-V600E degrader-2	BRAF-V600E, Kd: 9.5 nM Braf, Kd: 14.4 nM
VEGFR-2/BRAF-IN-2	BRaf^V600E, IC₅₀: 0.089 μM BRAF^WT, IC₅₀: 0.071 μM
SHR902275	BRaf^V600E, IC₅₀: 5.7 nM BRAF^WT, IC₅₀: 10 nM	c-Raf, IC₅₀: 1.6 nM
EGFR/BRAF-IN-1	BRaf^V600E, IC₅₀: 45 nM
PF-04880594	Braf	CRAF
Multi-kinase-IN-5	Braf
BRAFV600E-IN-1	BRaf^V600E
B-Raf IN 9	B-Raf, IC₅₀: 24.97 ± 0. nM
B-Raf IN 7	B-Raf, IC₅₀: 110.23 ± 0 nM
Agerafenib hydrochloride	BRaf^V600E, Kd: 14 nM Braf, Kd: 36 nM	CRAF, Kd: 39 nM
XL-281	B-Raf, IC₅₀: 4.5 nM B-Raf^V600E, IC₅₀: 6 nM	c-Raf, IC₅₀: 2.6 nM
SKLB646	B-Raf, IC₅₀: 0.022 μM	c-Raf, IC₅₀: 0.019 μM
SJ-C1044	BRAF^WT, IC₅₀: 331 nM BRaf^V600E, IC₅₀: 187 nM	CRAF, IC₅₀: 257 nM
B-Raf IN 18	B-Raf^V600E, IC₅₀: 3.8 nM
Raf inhibitor 1 dihydrochloride	B-Raf, Ki: 1 nM B-Raf^V600E, Ki: 1 nM	c-Raf, Ki: 0.3 nM

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4